Dr. van der Loo has been involved in the GMP manufacturing of viral vectors for early phase clinical trials since 2002. He received his PhD from the Erasmus University in Rotterdam in stem cell biology in 1995, completed a post-doctoral fellowship at Indiana University on a grant from the Howard Hughes Medical Institute, initiated a GMP Vector Production Facility at the Cincinnati Children’s Hospital Medical Center in 2002, and served as its director for 13 years. His expertise includes process development and manufacturing of several viral vector platforms including gamma-retrovirus, lentivirus and AAV. In addition, he has been involved in the design, commissioning, and validation of several GMP facilities. Currently, Dr. van der Loo is the Director of the Clinical Vector Core at the Children’s Hospital of Philadelphia. He is a member of the Editorial Board of Molecular Therapy – Methods & Clinical Development, a member of Translational Science and Product Development Committee of the American Society of Gene & Cell Therapy, a member of the 4Bio Ventures Management Advisory Board, and serves as consultant in several capacities.